tiaclor (50 mg + 200 mg)/g premiks do sporządzania paszy leczniczej
ceva sante animale - tiamulini hydrogenofumaras + chlortetracyclini hydrochloridum - premiks do sporządzania paszy leczniczej - (50 mg + 200 mg)/g - świnia
activus® 400 sc
adama - stężona zawiesina przeznaczona do rozcieńczania wodą (sc) - pendimetalina - herbicyd
dipeptiven 200 mg/ml koncentrat do sporządzania roztworu do infuzji
fresenius kabi deutschland gmbh - n(2)-l-alanyl-glutamine - koncentrat do sporządzania roztworu do infuzji - 200 mg/ml
vancomycin mylan 500 mg proszek do sporządzania roztworu do infuzji
mylan s.a.s. - vancomycini hydrochloridum - proszek do sporządzania roztworu do infuzji - 500 mg
vancomycin mylan 1 g proszek do sporządzania roztworu do infuzji
mylan s.a.s. - vancomycini hydrochloridum - proszek do sporządzania roztworu do infuzji - 1 g
imatinib actavis
actavis group ptc ehf - imatinib - leukemia, myelogenous, chronic, bcr-abl positive; precursor cell lymphoblastic leukemia-lymphoma; myelodysplastic-myeloproliferative diseases; hypereosinophilic syndrome; dermatofibrosarcoma - protein kinase inhibitors, antineoplastic agents - imatinib actavis is indicated for the treatment of: , paediatric patients with newly diagnosed philadelphia chromosome (bcr-abl) positive (ph+) chronic myeloid leukaemia (cml) for whom bone marrow transplantation is not considered as the first line of treatment;, paediatric patients with ph+ cml in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis;, adult patients with ph+ cml in blast crisis;, adult patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) integrated with chemotherapy;, adult patients with relapsed or refractory ph+ all as monotherapy;, adult patients with myelodysplastic/myeloproliferative diseases (mds/mpd) associated with platelet-derived growth factor receptor (pdgfr) gene re-arrangements;, adult patients with advanced hypereosinophilic syndrome (hes) and/or chronic eosinophilic leukaemia (cel) with fip1l1-pdgfr rearrangement;, the treatment of adult patients with unresectable dermatofibrosarcoma protuberans (dfsp) and adult patients with recurrent and/or metastatic dfsp who are not eligible for surgery. efekt imatinib na wynik przeszczepienia szpiku kostnego nie jest określona. imatinib actavis is indicated for: , in adult and paediatric patients, the effectiveness of imatinib is based on overall haematological and cytogenetic response rates and progression-free survival in cml, on haematological and cytogenetic response rates in ph+ all, mds/mpd, on haematological response rates in hes/cel and on objective response rates in adult patients with unresectable and/or metastatic dfsp. doświadczenie z imatinibom u pacjentów z mds/jest msy, związanych z pdgfr genów permutacji-bardzo ograniczony. brak kontrolowanych badań wykazują kliniczną korzyść lub zwiększone tempo dla tych chorób.
levothyroxine accord 12,5 mcg tabletki
accord healthcare polska sp. z o.o. - levothyroxinum natricum - tabletki - 12,5 mcg
levothyroxine accord 25 mcg tabletki
accord healthcare polska sp. z o.o. - levothyroxinum natricum - tabletki - 25 mcg
levothyroxine accord 50 mcg tabletki
accord healthcare polska sp. z o.o. - levothyroxinum natricum - tabletki - 50 mcg
levothyroxine accord 75 mcg tabletki
accord healthcare polska sp. z o.o. - levothyroxinum natricum - tabletki - 75 mcg